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SUMMARY
Escherichia coli is a Gram-negative, facultatively anaerobic, rod-shaped, coliform bacterium, 
which is a primary cause of urinary tract infections. Resistance to antibiotics has become a particular 
problem in recent decades. Consequently, there is an unmet need for new therapeutic options. It 
has been observed that essential oils have bactericidal effects. The antimicrobial susceptibility 
testing for Escherichia coli isolates obtained from urine of patients with urinary tract infections 
was determined via disk diffusion method according to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST, 2015). Essential oil from clove – Syzygium aromaticum (L.) Merill 
et L.M. (Myrtaceae) was analyzed by GC-FID-MS. Minimal Inhibitory Concentration (MIC) and 
Minimal Bactericidal Concentration (MBC) were detected by using the micro-dilution broth method. 
Escherichia coli clinical isolates are characterized by high resistance to ampicillin, amoxicillin 
with clavulanic acid, norloxacin, trimethoprim/sulfamethoxazole, tetracycline, tobramycin and 
ticarcillin. Clove oil possesses strong inhibiting and killing properties against E. coli isolates, among 
them the ones resistant to recommended antibiotics. The results of this study highlight the need for 
testing the eficacy of new agents to inactivate bacteria in clinical settings.
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Escherichia coli jest Gram-ujemną, względnie beztlenową bakterią, która jest główną 
przyczyną infekcji dróg moczowych. Oporność na antybiotyki staje się coraz większym problemem 
ostatnich dekad, dlatego istnieje ogromna potrzeba poszukiwania nowych terapii lekowych. 
Badanie wrażliwości na leki przeciwbakteryjne izolatów Escherichia coli wyizolowanych z moczu 
pacjentów z zakażeniami dróg moczowych określono metodą dyfuzyjno-krążkową według European 
Committee on Antimicrobial Susceptibility Testing (EUCAST, 2015). Skład olejku eterycznego 
z goździkowca korzennego – Syzygium aromaticum (L.) Merr&Perry (Myrtaceae) został określony 
metodą GC-FID-MS. Minimalne stężenie hamujące (MIC) i minimalne stężenie bójcze (MBC) 
zbadano, stosując metodę mikrorozcieńczeń. Izolaty kliniczne Escherichia coli charakteryzowały 
się wysoką opornością na ampicylinę, amoksycylinę z kwasem klawulanowym, norloksacynę, 
trimetoprim/sulfametoksazol, tetracyklinę, tobramycynę i tikarcylinę. Badanie wykazało silne 
właściwości hamujące i bójcze olejku goździkowego wobec izolatów E. coli, w tym opornych 
na rekomendowane antybiotyki. Wyniki wskazują na potrzebę badań nad skutecznością nowych 
środków do dezaktywacji bakterii w warunkach klinicznych.
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INTRODUCTION
Urinary tract infection (UTI) is one of the most common conditions observed in general 
practice, accounting for up to 6% of consultations. About 150 million people worldwide develop UTI 
each year (9). It affects more women than men (24). 20% of women at any time have asymptomatic 
bacteriuria and around 40% of them develop at least one UTI during their lifetime (19).
Urinary tract infection (UTI) is the presence of urinary tract microorganisms above the bladder 
– generally > 105 / ml (signiicant bacteriuria). Asymptomatic bacteriuria means that bacteria tend 
to multiply up to 105 colony-forming units (CFU) per ml without any clinical symptoms (17). 
Symptomatic UTIs are classiied as cystitis, pyelonephritis, and urosepsis, considering that the 
urosepsis syndrome is the most severe form and that pyelonephritis is more severe than cystitis 
(26). zacché and Giarenis classiied UTIs as either uncomplicated or complicated depending on the 
presence of structural or neurological urinary tract abnormalities (28). The risk factors are phenotyped 
according to the ORENUC system: O indicates unknown risk factors; R – risk of recurrent UTIs but 
without risk of a more severe outcome; E – extraurogenital risk factors; N – relevant nephropathic 
diseases; U – urologic resolvable (transient) risk factors; C – permanent external urinary catheter 
and unresolved urologic risk factors (14).
Most UTIs are caused by the ascent of microorganisms through the urethra, although some 
microorganisms can reach the urinary tract by hematogenous or lymphatic spread (11). Most UTIs 
are monomicrobial. The most common uropathogen in uncomplicated upper and lower urinary 
tract infections is Escherichia coli (70–95% of cases) and Staphylococcus saprophyticus (5–10% 
of cases) (4, 26). Occasionally there are isolated bacteria from Enterobacteriaceae family, such as 
Proteus mirabilis and Klebsiella spp. (20). The microbial spectrum of complicated UTIs is broader 
and includes species of Pseudomonas, Enterococcus, Staphylococcus, Serratia, and Providencia, 
viruses and fungi (21).
Escherichia coli is a Gram-negative, facultatively anaerobic, rod-shaped, coliform bacteria 
found in the lower intestine (25). Most E. coli strains are harmless, but some serotypes can cause 
serious disease (6). The harmless strains are part of the normal lora of the gut, can beneit their hosts 
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by producing vitamin K2 (3), and have a symbiotic relationship (13). Uropathogenic E. coli (UPEC) 
is one of the main causes of urinary tract infections. They are equipped with pathogenic factors like: 
Fimbriae P, Fimbrial Adhesins Dr and Capillary Afa II Afa III, and hly A cytolysin.
Bacterial infections of urinary tract are treated with antibiotics or chemotherapeutics, at the 
initial empirical treatment period, and then on the basis of antibiogram. Polish recommendations 
for treating UTI include amoxicillin (and other semisynthetic penicillins), cephalosporins (mostly 
II and III generation), carbapenems, aztreonam, trimethoprim-sulfamethoxazole, ciproloxacin, 
nitrofurantoin and the aminoglycosides. According to the World health Organization, antibiotic 
resistance is a growing problem which poses a serious threat to public health. The consequences 
of infection with resistant microorganisms can be severe: increased mortality, prolonged stays in 
hospital, loss of prophylaxis for patients undergoing surgery and other medical procedures, as well 
as increased costs of treatment (5). Therefore, new therapeutic options should be proposed. This 
proves the need to develop new therapeutic options. 
Strong antiseptic activity of essential oils has been known for many centuries. A large number 
of essential oils and their constituents have been investigated for their microbial properties against 
some bacteria. Clove oil is an essential oil extracted from the clove plant. There are three types 
of clove oil: bud oil derived from the lower-buds of S. aromaticum contains 60–90% of eugenol, 
leaf oil derived from the leaves contains 82–88% of eugenol, and stem oil derived from the twigs 
contains 90–95% of this compound (18). The antimicrobial activities of clove was proved against 
several bacteria and fungi which were the case of food contamination (27). Pure clove oil or mixes 
with rosemary oil were tested against E. coli and other bacteria. The results showed the strong 
growth inhibiting activity in concentration between 0.062% and 0.500% (v/v) (10).
The aim of this study was to investigate the patterns of resistance among E. coli isolates 
obtained from urine of patients with UTIs and check their susceptibility to clove essential oil.
MATERIALS AND METhODS
Escherichia coli clinical isolates were obtained from urine of patients with UTIs. The 
examination of urine samples was based on the presence of ≥ 105 CFU of microorganisms per ml in 
urine culture. The bacteria were cultured according to standard microbiological methods with the 
use of Columbia Agar (Graso, Poland) and Mac Conkey Agar (Graso, Poland). They were identiied 
using API 20 E tests (bioMerieux, France). Identiication was conirmed by using the automated 
instrument VITEK 2 (bioMerieux, France).
The antimicrobial susceptibility testing for Escherichia coli isolates was determined via disk 
diffusion method according to the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST, 2015). The following discs were used: AM – ampicillin (10 µg), AMC – amoxicillin/
clavulanic acid (20 µg /10 µg), CXM – cefuroxime (30 µg), CTX – cefotaxim (30 µg), CIP – 
ciproloxacin (5 µg), NOR-norloxacine (10 µg), SXT – trimethoprim/sulfamethoxazole (1.25 µg 
/23.75 µg), NT-nitrofurantoine (300 µg), CN-cefalexine (30 µg), TET – tetracycline (30 µg), ATM 
– aztreonam (30 µg), FOX – cefoxitin (30 µg), TGC – tigecycline (15 µg); CAz – ceftazidime 
(30 µg), TOB – tobramycin (10 µg), FEP – cefepime (30 µg), TIC – tikarcillin (75 µg).
Minimal Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) 
were detected by the use of the micro-dilution broth method. The tested essential oil was diluted 
in 96% ethanol PURE (POCh, Gliwice, Poland) yielding a concentration of 95% v/v of oils. This 
stock solution was mixed with a 100 µl Mueller-hinton Broth to obtain concentrations from 1.5 µl/
ml to 4.5 µl/ml and transferred to 96-well microtiter plates. An inoculum containing 1.5∙108 CFU in 
the amount of 10 µl per well was added to medium with various clove oil concentrations. The MIC 
was determined as the lowest concentration of oil which inhibits the visible growth of bacteria after 
24 hours of incubation at 37°C under aerobic conditions. The MBC was determined by transferring 
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cultures which were cultivated in higher than MIC concentrations of oil on Columbia Agar medium 
(Graso, Poland) and incubating them at 37ºC for 24 hours. The control media containing only 
alcohol did not inhibit the growth of bacterial isolates. The studies were repeated three times.
For the study purposes, essential oil from clove – Syzygium aromaticum (L.) (L.) Merr&Perry 
(Myrtaceae) was provided by POLLENA-AROMA, Poland. It was analyzed by GC-FID-MS in the 
Institute of General Food Chemistry, Łódź University of Technology. Identiication of components 
was based on the comparison of their MS spectra with those of the laboratory-made MS library, 
commercial libraries (NIST 98.1, Wiley Registry of Mass Spectral Data, 8th Ed. and MassFinder 3.1) 
and with literature data (1, 15) along with the retention indices on apolar column (Rtx-1, MassFinder 
3.1) associated with a series of alkanes with linear interpolation (C8-C26).The composition of the clove oil was found to meet the requirements of the European 
Pharmacopoeia 8 (7) and of the Polish Pharmacopoeia IX (22) for the two main components: eugenol 
amounted to 86.0% (required 75.0–88.0%) and β-caryophyllene to 9.8% (required 5.0–14.0).
RESULTS AND DISCUSSION
The eficacy of antibiotic treatment depends on the identiication and deter-
mination of the uropathogen pattern of resistance. In our study 96.7% of UPEC 
isolates showed resistance to ampicillin, 73.3% to amoxicillin with clavulanic 
acid, 86.7% to ciproloxacin, 53.3% to norloxacine and 56.7% to trimethoprim 
with sulfamethoxazole. It means that the tested E. coli isolates were character-
ized by high resistance to penicillin and other antibiotics recommended in UTI. 
UPEC isolates also showed high resistance to tetracycline (70.0%) and tobramy-
cin (46.7%). Among the cephalosporins, the most effective was ceftazidime (3.3% 
resistance), then: cefotaxim (6.7%), cefoxitin (13.3%) cefuroxime (16.7%), ce-
fepime (16.7%) and cefalexine (20.0%). 13.3% of E. coli isolates were resistant to 
nitrofurantoine. A number of sensitive and resistant strains of E. coli are presented 
in Table 1.
Table 1. Number of E. coli isolates resistant and sensitive to antibiotics
Number 
of e. coli 
isolates
Antimicrobial agents
AM AMC CXM CTX CiP NOR SXT Nt CN tEt AtM FOX TGC CAz TOB fEP tiC
resistant 29 22 5 4 4 16 17 4 6 22 1 4 2 1 15 5 26
Sensitive 1 8 25 26 26 14 13 26 24 8 29 26 28 29 15 25 4
The tree diagram, shown in Figure 1, groups the applied antibiotics in terms 
of their effect on the tested strains. 
The cluster analysis shows that among the used antibiotics 3 groups can be 
distinguished: the irst group includes antibiotics to which, most of E. coli isolates 
were resistant (AM, AMC, TET, TIC); the second group includes antibiotics for 
which the number of sensitive and resistant isolates is similar (TOB, SXT, NOR). 
The third group (CAz, ATM, NT, FOX, FEB, CTX, CN, TGC, CIP, CXM) col-
lects antibiotics for which the number of resistant isolates was the lowest.
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The effectiveness of clove oil against E. coli isolates suggests that it could po-
tentially be used as a supplement to UTI therapy or as an alternative therapy – all 
tested isolates were sensitive to studied oil. Based on preliminary studies, it was 
found that the MICs and MBCs for clove oil fall into the following range: MIC 
from 2.1 to 3.1 mg/ml and MBC from 3.1 to 4.2 mg/ml (Fig. 2). For more than 
70% of clinical strains of E. coli, MIC and MBC values were 2.6 and 3.7 mg/ml 
respectively (Tab. 2).
Fig. 1. Tree diagram of antibiotics sensitivity of E. coli isolates. The diagram was made using 
the full bindings and Euclidean distance method.
Table 2. Percentage of E. coli isolates in relation to MIC and MBC values determined for clove oil
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Saeed and Tariq (23) showed that the clove essential oil has a broad spectrum 
of antibacterial activity against Gram-negative bacteria. In this study clove oil 
inhibited the growth of all tested clinical isolates obtained from a range of clinical 
samples of stool, urine, blood and pus from wound. It was active against 100 
isolates belonging to 10 different species of Gram-negative bacilli: Escherichia 
coli, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter aerogenes, 
Klebsiella ozaenae, Klebsiella pneumoniae, Serratia marcescens, Salmonella 
typhi, Shigella dysenteriae and Vibrio cholera. The inhibition zones were between 
11.87 ± 3.22 for E. coli isolates and 23.75 ± 3.03 for V. cholera isolates, but 
no data on the composition of the tested commercial clove oil. Fagere and Al 
Magboul (8) investigations conirmed the very strong antibacterial properties of 
clove oil against Gram-negative and Gram-positive bacteria. According to their 
study conducted with the use of the cup plate agar diffusion method and the micro-
dilution method, the MIC of the clove oil against reference strains of Escherichia 
coli and Pseudomonas aeruginosa was 1.5 mg/ml, and the MBC against E. coli 
was 3.125 mg/ml and against P. aeruginosa was 6.25 mg/ml. We obtained the 
similar results of the MIC and MBC values in relation to the E. coli coming from 
urine, including those against isolates resistant to antibiotics recommended in UTI. 
Our tested clove essential oil was consisistent with the requirements for medical 
use. Other authors reported on the antibacterial and antifungal activity of clove 
essential oil also in combination with antimicrobial drugs and its potential in the 
treatment of urogenital infections (2). The clove essential oil is safe for humans at 
low concentrations. The World health Organization (WhO) established that the 
acceptable daily intake of clove oil per day is 2.5 mg/kg of weight in humans (16). 
The toxic effect has been proven for eugenol (as the main constituent), which is 
easily absorbed when administered orally, reaching rapidly plasma and blood with 
Fig. 2. Values of MIC and MBC E. coli isolates from urine determined for clove oil.
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mean half-lives of 14.0 h and 18.3 h, respectively. A cumulative effect has been 
hypothesized and associated to relieve of neuropathic pain after repeated daily 
administrations (12).
In conclusion, due to the fact that antibiotic resistant bacteria are a serious 
threat to public health worldwide, there is a need to search for new methods of 
controlling pathogens. A promising alternative to antibiotics are essential oils. 
Clove oil could be encapsulated and used as a supplement to conventional anti-
biotic treatment. The results of this study highlight the importance of testing the 
eficacy of new approaches to inactivate bacteria in clinically relevant settings.
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